**The primary driver of trader sentiment on full marijuana rescheduling from Schedule I is the bifurcated Trump administration process and its procedural timeline.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while leaving unlicensed or recreational marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling opened June 29, 2026, concluded by July 15, and closed its evidentiary record after opponents’ witnesses largely participated; post-hearing briefs followed, with the administrative law judge now preparing a recommended decision for the DEA Administrator’s final rule. A September 9, 2026, D.C. Circuit ruling rejected challenges seeking to block the partial rescheduling, allowing it to remain in effect during litigation. Market-implied probabilities for full rescheduling by year-end remain modest because any final rule faces further delays, potential court challenges, and the need for the complete administrative record to reach the Administrator. Upcoming steps include the ALJ recommendation and exceptions period, with resolution likely extending into late 2026 or beyond absent accelerated action.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$812,546 ปริมาณ
Sep 30, 2026
September 30
2%
December 31
22%
$812,546 ปริมาณ
September 30
$739 ปริมาณ
2%
December 31
$202,236 ปริมาณ
22%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on full marijuana rescheduling from Schedule I is the bifurcated Trump administration process and its procedural timeline.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while leaving unlicensed or recreational marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling opened June 29, 2026, concluded by July 15, and closed its evidentiary record after opponents’ witnesses largely participated; post-hearing briefs followed, with the administrative law judge now preparing a recommended decision for the DEA Administrator’s final rule.
A September 9, 2026, D.C. Circuit ruling rejected challenges seeking to block the partial rescheduling, allowing it to remain in effect during litigation. Market-implied probabilities for full rescheduling by year-end remain modest because any final rule faces further delays, potential court challenges, and the need for the complete administrative record to reach the Administrator. Upcoming steps include the ALJ recommendation and exceptions period, with resolution likely extending into late 2026 or beyond absent accelerated action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Jul 31, 2026, 5:46 PM ET
ปริมาณการซื้อขาย
$812,546วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jul 31, 2026, 5:46 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on full marijuana rescheduling from Schedule I is the bifurcated Trump administration process and its procedural timeline.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while leaving unlicensed or recreational marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling opened June 29, 2026, concluded by July 15, and closed its evidentiary record after opponents’ witnesses largely participated; post-hearing briefs followed, with the administrative law judge now preparing a recommended decision for the DEA Administrator’s final rule.
A September 9, 2026, D.C. Circuit ruling rejected challenges seeking to block the partial rescheduling, allowing it to remain in effect during litigation. Market-implied probabilities for full rescheduling by year-end remain modest because any final rule faces further delays, potential court challenges, and the need for the complete administrative record to reach the Administrator. Upcoming steps include the ALJ recommendation and exceptions period, with resolution likely extending into late 2026 or beyond absent accelerated action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$812,546วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jul 31, 2026, 5:46 PM ETผู้ตัดสินผล
0x65070BE91...**The primary driver of trader sentiment on full marijuana rescheduling from Schedule I is the bifurcated Trump administration process and its procedural timeline.** In April 2026, Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while leaving unlicensed or recreational marijuana in Schedule I. A separate expedited DEA administrative hearing on broader rescheduling opened June 29, 2026, concluded by July 15, and closed its evidentiary record after opponents’ witnesses largely participated; post-hearing briefs followed, with the administrative law judge now preparing a recommended decision for the DEA Administrator’s final rule. A September 9, 2026, D.C. Circuit ruling rejected challenges seeking to block the partial rescheduling, allowing it to remain in effect during litigation. Market-implied probabilities for full rescheduling by year-end remain modest because any final rule faces further delays, potential court challenges, and the need for the complete administrative record to reach the Administrator. Upcoming steps include the ALJ recommendation and exceptions period, with resolution likely extending into late 2026 or beyond absent accelerated action.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย